- Home
- EMO vs OMER Comparison
EMO vs OMER Comparison
Compare EMO & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMO
- OMER
- Stock Information
- Founded
- EMO 2011
- OMER 1994
- Country
- EMO United States
- OMER United States
- Employees
- EMO N/A
- OMER N/A
- Industry
- EMO Investment Managers
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- EMO Finance
- OMER Health Care
- Exchange
- EMO Nasdaq
- OMER Nasdaq
- Market Cap
- EMO 599.1M
- OMER 530.2M
- IPO Year
- EMO N/A
- OMER 2009
- Fundamental
- Price
- EMO $50.66
- OMER $8.37
- Analyst Decision
- EMO
- OMER Buy
- Analyst Count
- EMO 0
- OMER 4
- Target Price
- EMO N/A
- OMER $22.50
- AVG Volume (30 Days)
- EMO 27.1K
- OMER 650.0K
- Earning Date
- EMO 01-01-0001
- OMER 11-13-2024
- Dividend Yield
- EMO 6.70%
- OMER N/A
- EPS Growth
- EMO N/A
- OMER N/A
- EPS
- EMO N/A
- OMER N/A
- Revenue
- EMO N/A
- OMER N/A
- Revenue This Year
- EMO N/A
- OMER N/A
- Revenue Next Year
- EMO N/A
- OMER N/A
- P/E Ratio
- EMO N/A
- OMER N/A
- Revenue Growth
- EMO N/A
- OMER N/A
- 52 Week Low
- EMO $26.42
- OMER $2.61
- 52 Week High
- EMO $40.17
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- EMO 69.54
- OMER 42.71
- Support Level
- EMO $49.02
- OMER $8.87
- Resistance Level
- EMO $51.87
- OMER $9.50
- Average True Range (ATR)
- EMO 0.90
- OMER 0.77
- MACD
- EMO 0.38
- OMER -0.17
- Stochastic Oscillator
- EMO 77.92
- OMER 5.25
About EMO ClearBridge Energy Midstream Opportunity Fund Inc.
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.